BPG is committed to discovery and dissemination of knowledge
Cited by in CrossRef
For: Dajani AI, Popovic B. Essential phospholipids for nonalcoholic fatty liver disease associated with metabolic syndrome: A systematic review and network meta-analysis. World J Clin Cases 2020; 8(21): 5235-5249 [PMID: 33269259 DOI: 10.12998/wjcc.v8.i21.5235]
URL: https://www.wjgnet.com/1007-9327/full/v8/i21/5235.htm
Number Citing Articles
1
L. B. Lazebnik, E. V. Golovanova, S. V. Turkina, K. L. Raikhelson, S. V. Okovityy, O. M. Drapkina, I. V. Maev, A. I. Martynov, G. E. Roitberg, O. V. Khlynova, D. I. Abdulganieva, S. A. Alekseenko, M. D. Ardatskaya, I. G. Bakulin, N. V. Bakulina, A. O. Bueverov, E. V. Vinitskaya, G. V. Volynets, E. Yu. Eremina, V. B. Grinevich, A. I. Dolgushina, A. N. Kazyulin, E. I. Kashkina, I. V. Kozlova, Yu. V. Konev, N. V. Korochanskaya, Yu. A. Kravchuk, E. D. Li, I. D. Loranskaya, V. M. Makhov, S. N. Mekhtiev, V. P. Novikova, O. D. Ostroumova, Ch. S. Pavlov, V. G. Radchenko, A. A. Samsonov, A. S. Sarsenbaeva, R. G. Sayfutdinov, P. V. Seliverstov, S. I. Sitkin, O. V. Stefanyuk, L. V. Tarasova, E. I. Tkachenko, Yu. P. Uspensky, Yu. A. Fominykh, A. I. Khavkin, Yu. V. Tsyganova, O. O. Sharhun. Non-alcoholic fatty liver disease in adults: clinic, diagnostics, treatment. Guidelines for therapists, third versionExperimental and Clinical Gastroenterology 2021; 1(1): 4 doi: 10.31146/1682-8658-ecg-185-1-4-52
2
Asad Izziddin Dajani, Adnan Abuhammour. Agents for the treatment of fatty liver disease: focus on essential phospholipidsDrugs & Therapy Perspectives 2021; 37(6): 249 doi: 10.1007/s40267-021-00838-x
3
D. A. Teplyuk, M. Ch. Semenistaya, S. M. Sorokoletov, L. B. Lazebnik, Ch. S. Pavlov. Nonalcoholic liver disease: review with a focus on risks of progressionExperimental and Clinical Gastroenterology 2021; (8): 167 doi: 10.31146/1682-8658-ecg-192-8-167-174
4
Vladimir T. Ivashkin, Marina V. Maevskaya, Elena N. Shirokova, Igor V. Maev, Alexey A. Samsonov, Evgeniy I. Sas, Liudmila K. Palgova, Kirill Starostin. Correlation of Objective Endpoints and Subjective Patient-Reported Outcomes in NAFLD Treatment with Essential Phospholipids: Real-World Data Based on Pooled Analysis of Observational StudiesDrugs - Real World Outcomes 2021; 8(3): 369 doi: 10.1007/s40801-021-00250-x